Résultats de la recherche - Joseph Markowitz

iNOS is a key mediator of anti-PD-1 melanoma therapy response par Quang Tam Nguyen, Quang Tam Nguyen, Youngchul Kim, Youngchul Kim, Thi Hong Nga Le, Thi Hong Nga Le, Saurabh Garg, Vishanna Balkaran, Trisha Bhathivi, Alejandra Chamizo, Christopher W. Dukes, Kimberly Ward, Andrew S. Brohl, Andrew S. Brohl, Lilit Karapetyan, Lilit Karapetyan, Lilit Karapetyan, Nikhil I. Khushalani, Nikhil I. Khushalani, Zeynep Eroglu, Zeynep Eroglu, Ahmad A. Tarhini, Ahmad A. Tarhini, Ahmad A. Tarhini, Ahmad A. Tarhini, James J. Mulé, James J. Mulé, Joseph Markowitz, Joseph Markowitz, Joseph Markowitz, Joseph Markowitz

Accéder au texte intégral

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma par Joseph Markowitz, Ragini Kudchadkar, Jeffrey S. Weber, Zeynep Eroglu, Andrew S. Brohl, Nikhil I. Khushalani, Ram Thapa, Y. Ann Chen

Accéder au texte intégral

Predicting anti-PD-1 immune checkpoint blockade response in melanoma patients with spatially aware machine learning models par Alyssa Pybus, Raphael Kirchgaessner, Jonathan Nguyen, Carlos Moran Segura, Paulo Cilas Morais Lyra, Trevor Rose, Jhanelle Gray, Jeremy Goecks, Joseph Markowitz

Accéder au texte intégral

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy par Chad Pickering, Paul Aiyetan, Gege Xu, Alan Mitchell, Rachel Rice, Yana G. Najjar, Joseph Markowitz, Joseph Markowitz, Lisa M. Ebert, Lisa M. Ebert, Lisa M. Ebert, Michael P. Brown, Michael P. Brown, Michael P. Brown, Gonzalo Tapia-Rico, Dennie Frederick, Xin Cong, Daniel Serie, Klaus Lindpaintner, Flavio Schwarz, Genevieve M. Boland

Accéder au texte intégral

First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort par Tanya Ramadoss, Christian Palacios, Matthew Nichols, Zeynep Eroglu, Joseph Markowitz, Lilit Karapetyan, Ahmad A. Tarhini, Evan J. Wuthrick, Vernon K. Sondak, Kenneth Y. Tsai, Nikhil I. Khushalani, Andrew S. Brohl

Accéder au texte intégral

Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma par Joseph Markowitz, Ahmad A Tarhini, Zeynep Eroglu, Evan J Wuthrick, Andrew S Brohl, Nikhil I Khushalani, Vernon K Sondak, Lilit Karapetyan, Tanya Ramadoss, Matthew Nichols, Christian Palacios, Kenneth Y Tsai

Accéder au texte intégral

43 Harnessing the power of glycoproteomics: a cutting-edge approach for predicting treatment efficacy in metastatic melanoma with immune checkpoint inhibitors par Joseph Markowitz, Yana G Najjar, Michael P Brown, Dennie Frederick, Genevieve M Boland, Klaus Lindpaintner, Gege Xu, Rachel Rice, Daniel Serie, Lisa M Ebert, Alan Mitchell, Xin Cong, Gonzalo Tapia-Rico, Chad Pickering, Paul Aiyetan, Ranjan Bhadra, Chirag Dhar, Flavio Schwarz

625 Immune priming IFx-Hu2.0 promotes antibody responses necessary for anti-PD1 responses in PD-1 refractory melanoma patients par Joseph Markowitz, Shari Pilon-Thomas, Amod A Sarnaik, Pei-ling Chen, Ahmad A Tarhini, Zeynep Eroglu, Andrew S Brohl, Nikhil I Khushalani, Vernon K Sondak, Youngchul Kim, Michael Shamblott, Christopher W Dukes, Alejandra Chamizo, Marina Bastawrous, Edward Garcia, Ashraf Delhawi, Deanryan BDe Aquino, Patricia Lawman

Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial par Joseph Markowitz, Amod Sarnaik, Ahmad A Tarhini, Zeynep Eroglu, Evan J Wuthrick, Andrew S Brohl, Nikhil I Khushalani, Rogerio I Neves, Vernon K Sondak, Wenyi Fan, Younchul Kim, Kenneth Y Tsai, Matthew C Perez, Justin Martin, Lymon Sneed, Michael Harrington, Ricardo J Gonzalez, Jonathan S Zager, C Wayne Cruse

Accéder au texte intégral

ShinyEvents: harmonizing longitudinal data for real-world survival estimation par Alyssa Obermayer, Joshua Davis, Divya Priyanka Talada, Mingxiang Teng, Steven Eschrich, Vivien Yin, Daniel Spakowicz, Dipankor Chatterjee, Robert J. Rounbehler, Michelle L. Churchman, Ahmad A. Tarhini, Xuefeng Wang, Sumati Gupta, Joseph Markowitz, Jeremy Goecks, Roger Li, Rodrigo Rodrigues Pessoa, Brandon J. Manley, Aik-Choon Tan, G. Daniel Grass, Dung-tsa Chen, Timothy I. Shaw

Accéder au texte intégral